Get Access
TreelipClinical Program Risk Radar
Oncology Phase 2Methodology
NCT03712202

Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma

Public trial-level signal summary for this oncology Phase 2 record.

Back to reportOpen ClinicalTrials.gov
Record overview

Status and phase

Status: ACTIVE_NOT_RECRUITING

Phase: PHASE2

Sponsor: City of Hope Medical Center

Condition: Ann Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage I Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage I Nodular Sclerosis Classic Hodgkin Lymphoma, Ann Arbor Stage IA Hodgkin Lymphoma, Ann Arbor Stage IB Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma, Ann Arbor Stage IIA Hodgkin Lymphoma, Ann Arbor Stage IIB Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma, Ann Arbor Stage I Lymphocyte-Depleted Classic HL, Ann Arbor Stage II Lymphocyte-Depleted Classic HL, Ann Arbor Stage II Mixed Cellularity Classic HL, Ann Arbor Stage II Nodular Sclerosis Classic HL

Signal summary

Public flags

Status signal: Low Signal

Timeline signals: stale_update_signal | primary_completion_date_past_signal | completion_date_past_signal | long_recruitment_duration_signal

Results signal: Low Signal

Operational burden: strict_eligibility_signal

Stopped reason

Context when available

No stop reason available in the current public record.